Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004;21(4):363-9.
doi: 10.1023/b:clin.0000046176.33867.c5.

A BALB/c murine lung alveolar carcinoma used to establish a surgical spontaneous metastasis model

Affiliations
Free article

A BALB/c murine lung alveolar carcinoma used to establish a surgical spontaneous metastasis model

Michael McLean et al. Clin Exp Metastasis. 2004.
Free article

Abstract

Line-1, a weakly immunogenic lung tumor cell line derived from the BALB/c mouse, metastasizes spontaneously to the lungs of mice following subcutaneous administration. The parameters that influence metastasis as well as the progression of metastatic lung disease following surgical resection of primary subcutaneous tumors were characterized. Histological analysis of the lungs obtained from mice bearing different size subcutaneous tumors demonstrated that >90% of the mice developed micrometastatic disease in the lungs when the tumor exceeded 650 mm3 in size. Surgical resection of subcutaneous tumors resulted in the cure of primary disease in 95% of the mice. Macroscopic tumor nodules were grossly visible in the lungs of 75% of the mice 5 weeks after surgery. Serum amyloid A level correlated with primary tumor burden and was diagnostic for the presence of metastatic disease. The efficiency of metastasis, post-surgical primary tumor recurrence and long-term survival were significantly different between BALB/c mice obtained from different suppliers. The Line-1-BALB/c surgical metastasis model provides a clinically relevant tool for the evaluation of anti-cancer therapies, especially those that are designed to target long-term suppression of minimal residual disease following surgical intervention.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Int J Cancer. 1990 Apr 15;45(4):788-94 - PubMed
    1. Cancer Gene Ther. 1998 Nov-Dec;5(6):380-9 - PubMed
    1. Cell Immunol. 1995 Oct 15;165(2):217-24 - PubMed
    1. Clin Chem Lab Med. 2001 Feb;39(2):129-33 - PubMed
    1. Int J Cancer. 1995 May 29;61(5):628-34 - PubMed

Publication types